CRBN and Miyoshi myopathy: Given the documented association between CRBN expression and IMiD treatment response in patients with MM, some studies have also begun to explore single nucleotide variants (SNVs) in the CRBN gene as potentially useful biomarkers for the clinical assessment of antimyeloma efficacy, or patient selection for predicted responders before initiating therapy.